Zoledronic Acid in MS-patients With Osteoporosis

Inclusion Criteria

• •Inclusion:
• •Written informed consent to participate in the trial
• •Definite diagnosis of Multiple Sclerosis (MS) as defined by 2005 revised McDonald criteria
• •MS-subtype: Relapsing-remitting MS (RRMS), Secondary progressive MS (SPMS), Primary progressive MS (PPMS)
• •Expanded Disability Status Scale (Kurtzke's scale; EDSS) score between 2.5 to 6.5 (including both)
• •Bone mineral density (BMD) T-score of less or equal to -2.0 and more or equal to -4.0 at the lumbar spine (L1-L4 with at least 2 evaluable vertebrae) and/or total hip region and/or femoral neck in recent Dual X-Ray Absorptiometry (DXA)-scan (\< or = 3 months)
• •Sufficient ability to read, write and communicate comprehensibly and comply to study procedures
• •No immunomodulatory treatment for MS within the last 30 days or stable and well tolerated therapy with any beta-interferon formulation, or glatirameracetate or fingolimod for at least 30 days immediately prior to baseline